natgillin/translations-raw huggingface dataset:
The mean maximum anti-IIa activity level is observed approximately 3 to 4 hours following subcutaneous injection and reaches 0.13 IU/mL and 0.19 IU/mL following repeated administration of 100 IU/kg (1 mg/kg) twice daily and 150 IU/kg (1.5 mg/kg) once daily, respectively.
Srednja vrijednost vršne anti-IIa aktivnosti bilježi se približno 3 do 4 sata nakon supkutane injekcije te doseže vrijednosti od 0,13 IU/ml i 0,19 IU/ml nakon ponovljene primjene doze od 100 IU/kg (1 mg/kg) dvaput na dan odnosno 150 IU/kg (1,5 mg/kg) jedanput na dan.
Benzyl alcohol (150 mg in 10.0 mL)
Pomoćna(e) tvar(i) s poznatim učinkom Benzilni alkohol (150 mg u 10,0 ml)
The following medicinal products may be administered with caution concomitantly with enoxaparin sodium: Other medicinal products affecting haemostasis such as: - Platelet aggregation inhibitors including acetylsalicylic acid used at antiaggregant dose (cardioprotection), clopidogrel, ticlopidine, and glycoprotein IIb/IIIa antagonists indicated in acute coronary syndrome due to the risk of bleeding, - Dextran 40, - Systemic glucocorticoids.
Sljedeći se lijekovi mogu primjenjivati zajedno s enoksaparinnatrijem uz oprez: Ostali lijekovi koji utječu na hemostazu, kao što su: - inhibitori agregacije trombocita, uključujući acetilsalicilatnu kiselinu u antiagregacijskoj dozi (kardioprotekcija), klopidogrel, tiklopidin i antagoniste glikoproteina IIb/IIIa indicirane kod akutnog koronarnog sindroma zbog rizika od krvarenja - dekstran 40 - sistemski glukokortikoidi
Total VTE
Nemojte ga
For patients with creatinine clearance [15-30 mL/minute], additional considerations are necessary because elimination of enoxaparin sodium is more prolonged (see section 4.2).
Potrebno je dodatno razmotriti primjenu u bolesnika kojima je klirens kreatinina 15-30 ml/min jer je kod njih eliminacija enoksaparina dugotrajnija (vidjeti dio 4.2).
Intravenous (Bolus) Injection (for acute STEMI indication only)
Intravenska (bolusna) injekcija (samo za akutni STEMI)
Obese Patients
Pretili bolesnici
To obtain a 300 IU/mL (3 mg/mL) solution, using a 6,000 IU (60 mg) enoxaparin sodium pre-filled syringe, it is recommended to use a 50 mL infusion bag (i.e. using either normal sodium chloride 9 mg/mL (0.9%) solution for infusion or 5% glucose in water for injections) as follows:
Da bi se dobila otopina od 300 IU/ml (3 mg/ml) kada se koristi napunjena štrcaljka sa 6000 IU (60 mg) enoksaparinnatrija, preporučuje se upotrijebiti infuzijsku vrećicu volumena 50 ml (s običnom otopinom natrijeva klorida od 9 mg/ml (0,9 %) za infuziju ili 5 %-tnom vodenom otopinom glukoze za injekcije) na sljedeći način:
Dosage table for patients with severe renal impairment (creatinine clearance [15-30] mL/min):
Tablica za doziranje u bolesnika s teškim oštećenjem funkcije bubrega (klirens kreatinina: 15-30 ml/min)
• Bleeding.
• Krvarenje
One vial contains enoxaparin sodium 50,000 IU anti-Xa activity (equivalent to 500 mg) in 5.0 mL water for injections.
Jedna bočica sadrži 50 000 IU anti-Xa aktivnosti enoksaparinnatrija (što odgovara 500 mg) u 5,0 ml vode za injekcije.
For all indications except STEMI, no dose reduction is necessary in the elderly patients, unless kidney function is impaired (see below “renal impairment” and section 4.4).
Kod svih indikacija osim STEMI-ja nije potrebno prilagođavati dozu u starijih bolesnika, osim ako im je narušena bubrežna funkcija (vidjeti odlomak „
Very common: Thrombocytosi β
Vrlo često: trombocitoz β
Inhixa 4,000 IU (40 mg)/0.4 mL is 0.4 mL of solution in: - a clear, colourless type I neutral glass syringe barrel with fixed needle and needle shield closed by chlorobutyl rubber stopper and a yellow polypropylene plunger rod.
Inhixa 4000 IU (40 mg)/0,4 mL jest 0,4 ml otopine u: - štrcaljki s tijelom od prozirnog, bezbojnog neutralnog stakla tipa I, zatvorenoj čepom od klorbutil-gume i žutim klipom od polipropilena s pričvršćenom iglom i pokrovom za iglu.
Enoxaparin sodium is not recommended for patients with end stage renal disease (creatinine clearance < 15 mL/min) due to lack of data in this population outside the prevention of thrombus formation in extra corporeal circulation during haemodialysis.
Enoksaparinnatrij se ne preporučuje za bolesnike u terminalnoj fazi bubrežne bolesti (klirens kreatinina < 15 ml/min) zbog nedovoljno podataka o primjeni u toj populaciji kod svih indikacija osim sprječavanja nastanka krvnih ugrušaka u izvantjelesnoj cirkulaciji tijekom hemodijalize.
One vial (5.0 mL) contains 50,000 IU (500 mg) enoxaparin sodium.
Jedna bočica (5,0 ml) sadrži 50 000 IU (500 mg) enoksaparinnatrija.
The mean maximum plasma anti-Xa activity level is observed 3 to 5 hours after subcutaneous injection and achieves approximately 0.2, 0.4, 1.0 and 1.3 anti-Xa IU/mL following single subcutaneous administration of 2,000 IU, 4,000 IU, 100 IU/kg and 150 IU/kg (20 mg, 40 mg, 1 mg/kg and 1.5 mg/kg) doses, respectively.
Srednja vrijednost vršne plazmatske anti-Xa aktivnosti primjećuje se 3 do 5 sati nakon supkutane injekcije, a iznosi približno 0,2, 0,4, 1,0 odnosno 1,3 anti-Xa IU/ml nakon jednokratne supkutane primjene doze od 2000 IU (20 mg), 4000 IU (40 mg), 100 IU/kg (1 mg/kg) odnosno 150 IU/kg (1,5 mg/kg).
Percutaneous coronary revascularization procedures
Postupci perkutane koronarne intervencije
Solution for injection in multidose vial 1 vial
otopina za injekciju u višedoznoj bočici 1 bočica
In the clinical studies for treatment of unstable angina and non-Q-wave myocardial infarction, doses were 100 IU/kg (1 mg/kg) subcutaneously every 12 hours, and in the clinical study for treatment of acute STEMI enoxaparin sodium regimen was a 3,000 IU (30 mg) intravenous bolus followed by 100 IU/kg (1 mg/kg) subcutaneously every 12 hours.
U kliničkim ispitivanjima primjene za liječenje nestabilne angine i infarkta miokarda bez Q-zupca, doza je iznosila 100 IU/kg (1 mg/kg) supkutano svakih 12 sati, dok je u kliničkom ispitivanju primjene za liječenje akutnog STEMI-ja režim liječenja enoksaparinnatrijem uključivao primjenu intravenske bolusne doze od 3000 IU (30 mg), nakon koje se primjenjivala supkutana doza od 100 IU/kg (1 mg/kg) svakih 12 sati.
Common: Thrombocytosisβ
Često: trombocitopenija
Enoxaparin sodium 2,000 IU (20 mg) once a day subcutaneously n (%)
Enoksaparinnatrij 2000 IU (20 mg) jedanput na dan supkutano n (%)
Enoxaparin sodium is a low clearance drug with a mean anti-Xa plasma clearance of 0.74 L/h after a 150 IU /kg (1.5 mg/kg) 6-hour intravenous infusion.
Enoksaparinnatrij je lijek s niskom stopom klirensa; srednja vrijednost plazmatskog klirensa anti-Xa aktivnosti nakon 6-satne intravenske infuzije doze od 150 IU/kg (1,5 mg/kg) iznosi 0,74 l/h.
One pre-filled syringe (0.8 mL) contains 12,000 IU (120 mg) enoxaparin sodium.
Jedna napunjena štrcaljka (0,8 ml) sadrži 12 000 IU (120 mg) enoksaparinnatrija.
• you are going to receive spinal or epidural anesthesia or lumbar puncture (see section “Operations and
• ako ćete primiti spinalnu ili epiduralnu anesteziju ili ići na lumbalnu punkciju (pogledajte odlomak 'Operacije i anestetici'): mora se poštovati vremenski razmak između primjene lijeka
Changing from treatment with direct oral anticoagulant to Inhixa Stop taking direct oral anticoagulant.
Prelazak s liječenja direktnim oralnim antikoagulansima na Inhixu Prestanite uzimati direktni oralni antikoagulans.
CARTON (Packs of 1, 2, 6, 10, 20, 50 or 90)
KUTIJA (Pakiranje od 1, 2, 6, 10, 20, 50 ili 90)
Inhixa 15,000 IU (150 mg)/1 mL solution for injection
Inhixa 15 000 IU (150 mg)/1 ml otopina za injekciju
Anti-Xa exposure represented by AUC, at steady-state, is marginally increased in mild (creatinine clearance 50-80 mL/min) and moderate (creatinine clearance 30-50 mL/min) renal impairment after repeated SC 4,000 IU (40 mg) once daily doses.
Izloženost anti-Xa aktivnosti, izražena kao AUC, u stanju dinamičke ravnoteže neznatno je povišena kod blagog (klirens kreatinina: 50-80 ml/min) i umjerenog (klirens kreatinina: 30-50 ml/min) oštećenja bubrežne funkcije nakon ponovljene supkutane primjene doze od 4000 IU (40 mg) jedanput na dan.
- Changing from treatment with direct oral anticoagulant to Inhixa Stop taking direct oral anticoagulant.
- Prelazak s liječenja direktnim oralnim antikoagulansima na Inhixu Prestanite uzimati direktni oralni antikoagulans.
Benzyl alcohol (45 mg in 3.0 mL)
Pomoćna(e) tvar(i) s poznatim učinkom Benzilni alkohol (45 mg u 3,0 ml)
One vial contains enoxaparin sodium 30,000 IU anti-Xa activity (equivalent to 300 mg) in 3.0 mL water for injections.
Jedna bočica sadrži 30 000 IU anti-Xa aktivnosti enoksaparinnatrija (što odgovara 300 mg) u 3,0 ml vode za injekcije.
One vial (5 mL) contains 50,000 IU (500 mg) enoxaparin sodium.
Jedna bočica (5 ml) sadrži 50 000 IU (500 mg) enoksaparinnatrija.
Inhixa 30,000 IU (300 mg)/3 mL solution for injection in multidose vial
Inhixa 30 000 IU (300 mg)/3 ml otopina za injekciju u višedoznoj bočici
Although no dose adjustment is recommended in patients with moderate (creatinine clearance 30-50 mL/min) and mild (creatinine clearance 50-80 mL/min) renal impairment, careful clinical monitoring is advised.
Iako se ne preporučuje prilagođavanje doze u bolesnika s umjerenim (klirens kreatinina: 30-50 ml/min) i blagim (klirens kreatinina: 50-80 ml/min) oštećenjem bubrežne funkcije, preporučuje se pažljivo kliničko praćenje.
Although no dose adjustment is recommended in patients with moderate (creatinine clearance 3050 mL/min) and mild (creatinine clearance 50-80 mL/min) renal impairment, careful clinical monitoring is advised.
Iako se ne preporučuje prilagođavanje doze u bolesnika s umjerenim (klirens kreatinina: 3050 ml/min) i blagim (klirens kreatinina: 50 - 80 ml/min) oštećenjem bubrežne funkcije, preporučuje se pažljivo kliničko praćenje.
If a manual compression method is used, sheath should be removed 6 hours after the last intravenous/subcutaneous enoxaparin sodium injection.
Ako se provodi ručna kompresija, uvodnicu treba ukloniti 6 sati nakon posljednje intravenske./supkutane injekcije enoksparinnatrija.
One vial (3.0 mL) contains 30,000 IU (300 mg) enoxaparin sodium.
Jedna bočica (3,0 ml) sadrži 30 000 IU (300 mg) enoksaparinnatrija.
Each pre-filled syringe contains enoxaparin sodium 15,000 IU anti-Xa activity (equivalent to 150 mg) in 1 mL water for injections.
Jedna napunjena štrcaljka sadrži 15 000 IU anti-Xa aktivnosti enoksaparinnatrija (što odgovara 150 mg) u 1 ml vode za injekcije.
Enoxaparin sodium may be safely administered with sodium chloride 9 mg/ml (0.9%) solution for infusion or 5% glucose solution for injection (see section 4.2).
Enoksaparinnatrij može se sigurno primijeniti s otopinom natrijeva klorida od 9 mg/ml (0,9 %) za infuziju ili 5 %-tnom otopinom glukoze za injekciju (vidjeti dio 4.2).
One vial (3 mL) contains 30,000 IU (300 mg) enoxaparin sodium.
Jedna bočica (3 ml) sadrži 30 000 IU (300 mg) enoksaparinnatrija.
CARTON OF (Packs of 2, 5, 6, 10, 20, 30, 50 or 90)
KUTIJA (Pakiranje od 2, 5, 6, 10, 20, 30, 50 ili 90)
Inhixa 8,000 IU (80 mg)/0.8 mL is 0.8 mL of solution in: - a clear, colourless type I neutral glass graduated syringe barrel with fixed needle and needle shield closed by chlorobutyl rubber stopper and a red polypropylene plunger rod.
Inhixa 8000 IU (80 mg)/0,8 ml jest 0,8 ml otopine u: - graduiranoj štrcaljki s tijelom od prozirnog, bezbojnog neutralnog stakla tipa I, zatvorenoj čepom od klorbutil-gume i crvenim klipom od polipropilena, s pričvršćenom iglom i pokrovom za iglu.
Inhixa 4,000 IU (40 mg)/0.4 mL solution for injection
Inhixa 4000 IU (40 mg)/0,4 ml otopina za injekciju
Inhixa 15,000 IU (150 mg)/1 mL is 1 mL of solution in: - a clear, colourless type I neutral glass syringe barrel with fixed needle and needle shield closed by chlorobutyl rubber stopper and a dark blue polypropylene plunger rod.
Inhixa 15 000 IU (150 mg)/1 ml jest 1 ml otopine u: - štrcaljki s tijelom od prozirnog, bezbojnog neutralnog stakla tipa I, zatvorenoj čepom od klorbutil gume i tamnoplavim klipom od polipropilena, s pričvršćenom iglom i pokrovom za iglu.
Inhixa 10,000 IU (100 mg) /1 mL injection enoxaparin sodium
Inhixa 10 000 IU (100 mg)/1 ml otopina za injekciju enoksaparinnatrij
Inhixa 50,000 IU (500 mg)/5 mL solution for injection in multidose vial
Inhixa 50 000 IU (500 mg)/5 ml otopina za injekciju u višedoznoj bočici
Inhixa 6,000 IU (60 mg)/0.6 mL solution for injection
Inhixa 6000 IU (60 mg)/0,6 ml otopina za injekciju
Packs of: - 2, 10 and 30 pre-filled syringes, - 10 and 30 pre-filled syringes with a needle guard.
Pakiranja od: - 2, 10 i 30 napunjenih štrcaljke - 10 i 30 napunjenih štrcaljki sa štitnikom za iglu
One pre-filled syringe (0.4 mL) contains 4,000 IU (40 mg) enoxaparin sodium
Jedna napunjena štrcaljka (0,4 ml) sadrži 4000 IU (40 mg) enoksaparinnatrija.
Each pre-filled syringe of 0.8 mL contains 12,000 IU (120 mg) of enoxaparin sodium.
Jedna napunjena štrcaljka od 0,8 ml sadrži 12 000 IU (120 mg) enoksaparinnatrija.
Inhixa 2,000 IU (20 mg)/0.2 mL solution for injection
Inhixa 2000 IU (20 mg)/0,2 ml otopina za injekciju
Each pre-filled syringe contains enoxaparin sodium 4,000 IU anti-Xa activity (equivalent to 40 mg) in 0.4 mL water for injections.
Jedna napunjena štrcaljka sadrži 4000 IU anti-Xa aktivnosti enoksaparinnatrija (što odgovara 40 mg) u 0,4 ml vode za injekcije.
Each pre-filled syringe contains enoxaparin sodium 6,000 IU anti-Xa activity (equivalent to 60 mg) in 0.6 mL water for injections.
Jedna napunjena štrcaljka sadrži 6000 IU anti-Xa aktivnosti enoksaparinnatrija (što odgovara 60 mg) u 0,6 ml vode za injekcije.
One vial (10.0 mL) contains 100,000 IU (1000 mg) enoxaparin sodium.
Jedna bočica (10,0 ml) sadrži 100 000 IU (1000 mg) enoksaparinnatrija.
Inhixa 8,000 IU (80 mg)/0.8 mL solution for injection
Inhixa 8000 IU (80 mg)/0,8 ml otopina za injekciju
• Inhixa can be given by injection into your vein (intravenous) after certain types of heart attack or operation.
• Nakon određenih vrsta srčanog udara ili operacija, Inhixa se može primijeniti injekcijom u venu
Changing of anticoagulant treatment - Changing from Inhixa to blood thinners called vitamin-K antagonists (e.g. warfarin) Your doctor will request you perform blood tests called INR and tell you when to stop Inhixa accordingly.
Promjena antikoagulansa - Prelazak s lijeka Inhixa na lijekove za razrjeđivanje krvi koji se zovu antagonisti vitamina K (npr. varfarin)
Inhixa 12,000 IU (120 mg)/0.8 mL solution for injection
Inhixa 12 000 IU (120 mg)/0,8 ml otopina za injekciju
In clinical studies, haemorrhages, thrombocytopenia and thrombocytosis were the most commonly reported reactions (see section 4.4 and 'Description of selected adverse reactions' below).
U kliničkim su ispitivanjima najčešće prijavljene nuspojave bile krvarenja, trombocitopenija i trombocitoza (vidjeti dio 4.4 i odlomak „Opis odabranih nuspojava” u nastavku).
In clinical studies, haemorrhages, thrombocytopenia and thrombocytosis were the most commonly reported reactions (see sections 4.4 and “Description of selected adverse reactions” below).
U kliničkim su ispitivanjima najčešće prijavljene nuspojave bile krvarenja, trombocitopenija i trombocitoza (vidjeti dijelove 4.4 i „Opis odabranih nuspojava“ u nastavku).
Each pre-filled syringe of 0.4 mL contains 4,000 IU (40 mg) of enoxaparin sodium.
Jedna napunjena štrcaljka od 0,4 ml sadrži 4000 IU (40 mg) enoksaparinnatrija.
Weight
Sljedivost
Each pre-filled syringe of 0.6 mL contains 6,000 IU (60 mg) of enoxaparin sodium.
Jedna napunjena štrcaljka od 0,6 ml sadrži 6000 IU (60 mg) enoksaparinnatrija.
Switch between enoxaparin sodium and direct oral anticoagulants (DOAC) For patients currently receiving enoxaparin sodium, discontinue enoxaparin sodium and start the DOAC 0 to 2 hours before the time that the next scheduled administration of enoxaparin sodium would be due as per DOAC label.
U bolesnika koji trenutno primaju enoksaparinnatrij, njegovu primjenu treba prekinuti, a primjenu DOAK-a započeti 0 do 2 sata prije nego što je trebala biti primijenjena sljedeća doza enoksaparinnatrija, u skladu s informacijama iz sažetka opisa svojstava lijeka za DOAK.
After dilution with sodium chloride 9 mg/ml (0.9%) solution for infusion or 5% glucose solution for injection
Nakon razrjeđivanja otopinom natrijeva klorida od 9 mg/ml (0,9 %) za infuziju ili 5 %-tnom otopinom glukoze za injekciju
Each pre-filled syringe of 1 mL contains 15,000 IU (150 mg) of enoxaparin sodium.
Jedna napunjena štrcaljka od 1 ml sadrži 15 000 IU (150 mg) enoksaparinnatrija.
One pre-filled syringe (1 mL) contains 15,000 IU (150 mg) enoxaparin sodium
Jedna napunjena štrcaljka (1 ml) sadrži 15 000 IU (150 mg) enoksaparinnatrija.
CARTON OF (Packs of 2, 6, 10, 12, 24, 30, 50 or 90)
KUTIJA (Pakiranje od 2, 6, 10, 12, 24, 30, 50 ili 90)
CARTON OF (Packs of 2, 6, 10, 12, 24 or 30)
KUTIJA (Pakiranje od 2, 6, 10, 12, 24 ili 30)
CARTON OF (Packs of 2, 6, 10, 12, 20, 24 or 30)
KUTIJA (Pakiranje od 2, 6, 10, 12, 20, 24 ili 30)
Inhixa 30,000 IU (300 mg)/3 mL solution for injection in multidose vial enoxaparin sodium
Inhixa 30 000 IU (300 mg)/3 ml otopina za injekciju u višedoznoj bočici enoksaparinnatrij
One pre-filled syringe (0.2 mL) contains 2,000 IU (20 mg) enoxaparin sodium
Jedna napunjena štrcaljka (0,2 ml) sadrži 2000 IU (20 mg) enoksaparinnatrija.
One vial contains enoxaparin sodium 100,000 IU anti-Xa activity (equivalent to 1000 mg) in 10.0 mL water for injections.
Jedna bočica sadrži 100 000 IU anti-Xa aktivnosti enoksaparinnatrija (što odgovara 1000 mg) u 10,0 ml vode za injekcije.
Each pre-filled syringe of 0.8 mL contains 8,000 IU (80 mg) of enoxaparin sodium.
Jedna napunjena štrcaljka od 0,8 ml sadrži 8000 IU (80 mg) enoksaparinnatrija.
One pre-filled syringe (0.6 mL) contains 6,000 IU (60 mg) enoxaparin sodium
Jedna napunjena štrcaljka (0,6 ml) sadrži 6000 IU (60 mg) enoksaparinnatrija.
Switch between enoxaparin sodium and oral anticoagulants Switch between enoxaparin sodium and vitamin K antagonists (VKA) Clinical monitoring and laboratory tests [prothrombin time expressed as the International Normalized Ratio (INR)] must be intensified to monitor the effect of VKA.
Prelazak s enoksaparinnatrija na oralne antikoagulanse i obratno Prelazak s enoksaparinnatrija na antagoniste vitamina K i obratno Kliničko praćenje i laboratorijske pretrage (protrombinsko vrijeme izraženo kao internacionalni normalizirani omjer [engl. international normalized ratio, INR] moraju se intenzivirati radi praćenja učinka antagonista vitamina K.
Inhixa 15,000 IU (150 mg)/1 mL injection enoxaparin sodium
Inhixa 15 000 IU (150 mg)/1 ml otopina za injekciju enoksaparinnatrij
Inhixa 6,000 IU (60 mg)/0.6 mL is 0.6 mL of solution in: - a clear, colourless type I neutral glass graduated syringe barrel with fixed needle and needle shield closed by chlorobutyl rubber stopper and an orange polypropylene plunger rod.
Inhixa 6000 IU (60 mg)/0,6 ml jest 0,6 ml otopine u: - graduiranoj štrcaljki s tijelom od prozirnog, bezbojnog neutralnog stakla tipa I, zatvorenoj čepom od klorbutil-gume i narančastim klipom od polipropilena, s pričvršćenom iglom i pokrovom za iglu.
Each pre-filled syringe contains enoxaparin sodium 12,000 IU anti-Xa activity (equivalent to 120 mg) in 0.8 mL water for injections.
Jedna napunjena štrcaljka sadrži 12 000 IU anti-Xa aktivnosti enoksaparinnatrija (što odgovara 120 mg) u 0,8 ml vode za injekcije.
Inhixa 100,000 IU (1000 mg)/10 mL solution for injection in multidose vial
Inhixa 100 000 IU (1000 mg)/10 ml otopina za injekciju u višedoznoj bočici
Each pre-filled syringe contains enoxaparin sodium 8,000 IU anti-Xa activity (equivalent to 80 mg) in 0.8 mL water for injections.
Jedna napunjena štrcaljka sadrži 8000 IU anti-Xa aktivnosti enoksaparinnatrija (što odgovara 80 mg) u 0,8 ml vode za injekcije.
Solution for injection 2 pre-filled syringes 10 pre-filled syringes 30 pre-filled syringes 10 pre-filled syringes with needle guard 30 pre-filled syringes with needle guard
10 napunjenih štrcaljki 30 napunjenih štrcaljki 10 napunjenih štrcaljki sa štitnikom za iglu 30 napunjenih štrcaljki sa štitnikom za iglu
Skin necrosis / cutaneous vasculitis
Nekroza kože / kožni vaskulitis
Inhixa 10,000 IU (100 mg)/1 mL is 1 mL of solution in: - a clear, colourless type I neutral glass graduated syringe barrel with fixed needle and needle shield closed by chlorobutyl rubber stopper and a black polypropylene plunger rod.
Inhixa 10,000 IU (100 mg)/1 ml jest 1 ml otopine u: - graduiranoj štrcaljki s tijelom od prozirnog, bezbojnog neutralnog stakla tipa I, zatvorenoj čepom od klorbutil-gume i crnim klipom od polipropilena, s pričvršćenom iglom i pokrovom za iglu.
Thrombocytopenia and thrombocytosis System Organ
Trombocitopenija i tromboza
Inhixa 12,000 IU (120 mg)/0.8 mL injection enoxaparin sodium
Inhixa 12 000 IU (120 mg)/0,8 ml otopina za injekciju enoksaparinnatrij
Each pre-filled syringe contains enoxaparin sodium 10,000 IU anti-Xa activity (equivalent to 100 mg) in 1 mL water for injections.
Jedna napunjena štrcaljka sadrži 10 000 IU anti-Xa aktivnosti enoksaparinnatrija (što odgovara 100 mg) u 1 ml vode za injekcije.
Inhixa 8,000 IU (80 mg)/0.8 mL injection enoxaparin sodium
Inhixa 8000 IU (80 mg)/0,8 ml otopina za injekciju enoksaparinnatrij
The air bubble should not be expelled from the syringe before the injection to avoid the loss of drug when using pre-filled syringes.
Kako ne bi došlo do gubitka lijeka kod uporabe napunjenih štrcaljki, prije primjene injekcije ne smije se uklanjati mjehurić zraka iz štrcaljke.
Inhixa 4,000 IU (40 mg) /0.4 mL injection enoxaparin sodium
Inhixa 4000 IU (40 mg)/0,4 ml otopina za injekciju enoksaparinnatrij
The syringe can be additionally equipped with needle guard; or - a clear, colourless type I neutral glass graduated syringe barrel with fixed needle and needle shield closed by chlorobutyl rubber stopper and a white polycarbonate plunger rod equipped with UltraSafe Passive needle guard.
Štrcaljka može biti dodatno opremljena štitnikom za iglu; ili - graduiranoj štrcaljki s tijelom od prozirnog, bezbojnog neutralnog stakla tipa I, zatvorenoj čepom od klorbutil-gume i bijelim polikarbonatnim klipom, s pričvršćenom iglom pokrovom za iglu, opremljenoj UltraSafe Passive štitnikom za iglu.
Each pre-filled syringe contains enoxaparin sodium 2,000 IU anti-Xa activity (equivalent to 20 mg) in 0.2 mL water for injections.
Jedna napunjena štrcaljka sadrži 2000 IU anti-Xa aktivnosti enoksaparinnatrija (što odgovara 20 mg) u 0,2 ml vode za injekcije.
Each mL contains 10,000 IU (100 mg) enoxaparin sodium.
Jedan ml sadrži 10 000 IU (100 mg) enoksaparinnatrija.
Switch between enoxaparin sodium and vitamin K antagonists (VKA) Clinical monitoring and laboratory tests [prothrombin time expressed as the International Normalized Ratio (INR)] must be intensified to monitor the effect of VKA.
Prelazak s enoksaparinnatrija na antagoniste vitamina K i obratno Kliničko praćenje i laboratorijske pretrage (protrombinsko vrijeme izraženo kao internacionalni normalizirani omjer [engl. international normalized ratio, INR] moraju se intenzivirati radi praćenja učinka antagonista vitamina K.
One pre-filled syringe (0.8 mL) contains 8,000 IU (80 mg) enoxaparin sodium
Jedna napunjena štrcaljka (0,8 ml) sadrži 8000 IU (80 mg) enoksaparinnatrija.
Inhixa 6,000 IU (60 mg)/0.6 mL injection enoxaparin sodium
Inhixa 6000 IU (60 mg)/0,6 ml otopina za injekciju enoksaparinnatrij
Each pre-filled syringe of 0.2 mL contains 2,000 IU (20 mg) of enoxaparin sodium.
Jedna napunjena štrcaljka od 0,2 ml sadrži 2000 IU (20 mg) enoksaparinnatrija.
Volume to be injected through intravenous line after dilution is completed at a concentration of 300 IU (3 mg)/mL.
Volumen koji treba injicirati kroz intravensku liniju nakon završetka razrjeđivanja do koncentracije od 300 IU (3 mg)/ml.
The complete contents of the 6,000 IU (60 mg) enoxaparin sodium pre-filled syringe should be injected into the 20 mL remaining in the bag.
Injicirati sav sadržaj napunjene štrcaljke sa 6000 IU (60 mg) enoksaparinnatrija u 20 ml otopine koja je preostala u vrećici.
Each pre-filled syringe of 1 mL contains 10,000 IU (100 mg) of enoxaparin sodium.
Jedna napunjena štrcaljka od 1 ml sadrži 10 000 IU (100 mg) enoksaparinnatrija.